Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
This study shows the feasibility of using real-world data for the development of a population PK model. Evaluation and comparison of the model for Bayesian forecasting resulted in similar results as a model developed using rich sampling data.
Condition: Acquired Hemophilia A Intervention: Biological: TAK-672 Sponsor: Takeda Not yet recruiting
NEW YORK&BRISBANE, Calif.--(BUSINESS WIRE) October 07, 2020 -- Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE...
Condition: Haemophilia A Intervention: Drug: Turoctocog alfa pegol (N8-GP) Sponsor: Novo Nordisk A/S Not yet recruiting
Condition: Haemophilia A and B Intervention: Other: NON INTERVENTIONAL Sponsor: CHU de Reims Recruiting